Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report.

Abstract

A prospective, non-comparative study design was used to describe our experience with a bromelain-derived debriding agent, Debridase, in 130 patients with 332 deep second degree and third degree burns treated between 1984 and 1999. Debridase was applied after saturating the burns with a moist dressing for 2-24h. Debridase was applied for a period of 4h under an occlusive dressing. Mean patient age was 18.6 +/- 19.3, 42 (32.3%) were female, and 63 (48.5%) were children under age 18. Most burns were small. Debridase was applied once in 241 (72.6%) of the 332 wounds, twice in 67 (20.18%) cases, three times in 12 (3.61%) cases, and four times in 2 (0.6%) cases. The percentage debridement by number of applications was 89 +/- 21% for a single application, 77 +/- 27% for two, and 62 +/- 27% for three Debridase applications, respectively. There were no significant adverse events. The availability of a fast acting, reliable and complication-free enzymatic debriding agent may open new horizons and provide a new treatment modality for burns.

• Authors: Lior Rosenberg, Oren Lapid, Alex Bogdanov-Berezovsky, Ronen Glesinger, Yuval Krieger, Eldad Silberstein, Amiram Sagi, Keith Judkins, Adam J Singer
• Journal: Burns : journal of the International Society for Burn Injuries (Burns) Vol. 30 Issue 8 Pg. 843-50 (Dec 2004) ISSN: 0305-4179 [Print] Netherlands
• PMID: 15555800 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Keratolytic Agents
• Bromelains

Topics

• Adolescent
• Adult
• Bromelains (adverse effects, therapeutic use)
• Burns (physiopathology, surgery)
• Debridement (methods)
• Female
• Humans
• Keratolytic Agents (therapeutic use)
• Male
• Occlusive Dressings
• Prospective Studies
• Treatment Outcome
• Wound Healing (physiology)